Loading organizations...
Key people at Dynavax Technologies.
Dynavax Technologies is a commercial-stage biopharmaceutical company based in Emeryville, California, that develops and commercializes vaccines utilizing its proprietary CpG 1018 adjuvant technology to enhance immune responses. The organization's flagship product is HEPLISAV-B, a two-dose hepatitis B vaccine approved by the FDA to prevent infection across all known subtypes of the virus in adults. Operating as a publicly traded entity on the NASDAQ exchange under the ticker DVAX, the firm generates approximately $294.6 million in recent annual revenue and employs between 166 and 405 personnel. Following a 2019 reorganization to focus exclusively on vaccines, the enterprise supplied its adjuvant technology for nearly one billion vaccine doses worldwide and has previously engaged in strategic partnerships with pharmaceutical leaders like Merck. The company was originally incorporated during August 1996 by founders Michael Ostrakhovsky and Hasmukh Wani.
Dynavax Technologies Corporation (DVAX) is a commercial-stage biopharmaceutical company headquartered in Emeryville, California, focused on developing and commercializing innovative vaccines and immunotherapies, primarily targeting infectious diseases and immunology.[1][2] Its flagship product, HEPLISAV-B, is a hepatitis B vaccine for adults aged 18 and older, generating $154.2 million in 2023 revenue and capturing 8.7% of the hepatitis B vaccine market; the company also offers CpG 1018, an adjuvant used in HEPLISAV-B and other vaccines, alongside a pipeline including SD-101 immunotherapy, rF1V (plague vaccine in Phase 2), and Z-1018 (shingles vaccine candidate in Phase 1/2).[1][2] Dynavax serves hospitals, clinics, public health entities, the Department of Defense, Veterans Affairs, and pharmacies via wholesalers, addressing unmet needs in adult vaccination and immunotherapy with 2023 revenue of $701.1 million, net income of $154.3 million, and $187.5 million in R&D investment across 7 active clinical trials.[1][2]
Dynavax Technologies was incorporated in August 1996 as Double Helix Corporation in Berkeley, California (later relocating headquarters to Emeryville), and quickly renamed Dynavax Technologies Corporation in September 1996.[1][2] The company's early focus emerged from advancing Toll-like receptor (TLR) agonist-based technologies for vaccines and immunotherapies, leading to its IPO on February 19, 2004.[2] Pivotal moments include FDA approval of HEPLISAV-B in 2017 after prior setbacks, commercialization ramp-up, and partnerships like those with the U.S. Department of Defense, Coalition for Epidemic Preparedness Innovations, and Zhejiang Clover Biopharmaceuticals for CpG 1018 in COVID-19 vaccines, driving growth in infectious disease prevention.[1][2]
Dynavax stands out in biopharma through its proprietary CpG 1018 adjuvant platform, which enhances immune responses in vaccines like HEPLISAV-B, offering superior seroprotection rates compared to traditional hepatitis B vaccines, especially in adults and hemodialysis patients.[1][2]
Dynavax rides the wave of rising demand for novel adjuvants and adult vaccines amid global infectious disease threats, post-COVID emphasis on rapid vaccine tech, and aging populations needing shingles/hepatitis prevention.[1][2] Timing aligns with market forces like U.S. government stockpiling (e.g., plague vaccine) and international collaborations for pandemic preparedness, where CpG 1018's proven efficacy in COVID boosters amplifies influence.[2] It contributes to the biopharma ecosystem by licensing adjuvant tech, supporting partners like Clover Biopharma, and filling gaps in adult immunization rates, which lag pediatric vaccines, while influencing R&D in TLR-based therapies for oncology and autoimmunity.[1][2]
Dynavax's trajectory points to pipeline milestones like Phase 2/3 data for rF1V and Z-1018, potential HEPLISAV-B label expansions (e.g., hemodialysis), and adjuvant licensing deals amid biopharma M&A trends.[1][2] Trends like mRNA-adjuvant combos and government vaccine contracts will shape growth, potentially evolving its role from niche player to key supplier in global health security. With a $1.2B market cap and profitability, expect accelerated expansion if trials succeed, reinforcing its mission to innovate vaccines from the ground up.[1]
Key people at Dynavax Technologies.
